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Modern iodinated radiocontrast media are all based on the triiodinated benzene ring with various chemical modifications having
been made over the last few decades in order to reduce their toxicity. However, CIN remains a problem especially in patients with
pre-existing renal failure. In vitro studies have demonstrated that all RCM are cytotoxic. RCM administration in vivomay lead to a
decrease in renal medullary oxygenation leading to the generation of reactive oxygen species that may cause harmful effects to renal
tissue. In addition, endothelin and adenosine release and decreased nitric oxide levels may worsen the hypoxic milieu. In vitro cell
culture studies together with sparse in vivo rat model data have shown that important cell signalling pathways are affected by RCM.
In particular, the prosurvival and proproliferative kinases Akt and ERK1/2 have been shown to be dephosphorylated (deactivated),
whilst proinflammatory/cell death molecules such as the p38 and JNK kinases and the transcription factor NF-𝜅Bmay be activated
by RCM, accompanied by activation of apoptotic mediators such as caspases. Increasing our knowledge of themechanisms of RCM
action may help to develop future therapies for CIN.
1. Introduction
Radiocontrast media (RCM) are commonly used in med-
ical practice, but their use may lead to contrast-induced
nephropathy (CIN). The continued growth in radiographic
examinations means that increasing numbers of patients are
exposed to RCM, which in turn has resulted in increasing
incidence of CIN. CIN is the third most common cause
of hospital-acquired kidney failure accounting for 12% of
all cases [1, 2]. Whilst the toxicity of RCM is not fully
understood, it is believed to be due to many factors, the two
possible principal mechanisms being their effects on renal
hemodynamics and direct toxicity on renal cells [3, 4].
The opacity of iodine to X-rays renders it a suitable
compound as a contrastmedium.However, due to its toxicity,
iodine is not suitable to be used in itsmolecular or ionic form.
Whilst many iodinated organic compounds (with covalently
bound iodine within the molecule) had been proposed, the
search was for a compound that was less toxic, more soluble,
and having more opacity (i.e. containing more iodine atoms
per molecule). It was in the 1950s that certain derivatives
of iodinated benzoic acid were suggested as possible safe
contrast media [5], and since then, all modern iodinated
contrast media are based on the triiodinated benzene ring.
The ratio of iodine atoms to dissolved particles is important
since a greater number of iodine atoms would give better
opacification and fewer particles in solution would result
in a lower osmotic effect, and bearing these characteristics
in mind, the evolution of the RCM have involved succes-
sive chemical modifications. Firstly, hydrogen atoms on the
benzene ring were substituted with acetamido groups to
reduce protein binding (protein bindingwas believed to cause
anaphylactoid reactions) giving rise to the acetrizoates and
diatrizoates. These compounds are ionic and dissociate in
Hindawi Publishing Corporation
BioMed Research International
Volume 2014, Article ID 249810, 10 pages
http://dx.doi.org/10.1155/2014/249810
2 BioMed Research International
solution and are termed as high-osmolar contrast media
(HOCM). Then the carboxyl groups were replaced by non-
polar groups giving nonionic soluble molecules with lower
osmolality. These were termed as the low-osmolar contrast
media (LOCM) and were further improved by the addition
of more hydroxyl groups for increased hydrophilicity and
then a more even distribution of the hydroxyl groups on
the molecule. Finally, the dimerization of two molecules via
side chains on the benzene ring gave rise to the nonionic
iso-osmolar contrast media (IOCM) with increased iodine
atoms per molecule [6]. Of interest is the RCM ioxaglate
that whilst it is ionic, it is classified as an LOCM as it is a
dimer containing more iodine atoms per particle in solution.
A summary of the most commonly used RCM are presented
in Table 1.The improvements in contrast media development
have resulted in the acknowledgement that, in clinical use,
the newer LOCM and ICOM are less toxic than the original
HOCM [7], but in vitro cell culture studies have suggested
that all types of RCM have a direct toxic effect in many
different types of cells (see Table 2). It has been suggested that
molecular iodine may be present in solutions of RCM due to
degradation [8], but this may be negligible in solutions that
have been properly stored. Moreover, a study has shown that
incubating isolated proximal tubule segments with varying
concentrations of NaI had no adverse effects on cell viability
[9], and a further study showed that sodium iodide alone did
not cause significant cell death in cultured renal cells [10].
2. Toxicity of Radiocontrast Media in
In Vitro Cell Culture Studies
Many in vitro studies have investigated the toxicity of RCM
using different types of cultured cells, including renal epithe-
lial cells, mesangial cells, endothelial cells, smooth muscle
cells, hepatic cells, human fibroblasts, pulmonary mast cells,
human embryonic kidney cells, and human neutrophils.
The most common in vitro studies addressing the patho-
physiology of RCM-induced apoptosis have been criticized
because of their limitations which include: (1) the assessment
of only one potential mechanism of the RCM-induced renal
cell damage in the absence of several conflicting variables
that can be found in vivo; (2) the exposure to a constant
concentration of RCM to all cell lines, whereas in vivo, the
more distal epithelial tubular cells are exposed to a much
higher concentration than the proximal tubular cells; (3) the
potentially high dose of RCM commonly used for the cell
culture experiments; (4) the fact that effects of the RCM are
usually investigated as cellular “short term”-induced effects
(i.e. just after their exposure to cells), not along several hours
(as “long term” effects) of exposure to them. Finally, research
groups rarely compare different types of RCM (especially
those with different osmolarities) in the same study.
The most commonly used types of renal tubular cells for
in vitro studies include the canine-derived MDCK cells (a
model of distal tubular cells), the porcine cell line LLC-PK1
(a model of proximal tubular cells), and the humanHK-2 cell
line. The last one is a commonly used immortalized human
proximal tubular cell line which retains the phenotypic
expression and functional characteristic of human proximal
tubular cells, as described by others [29, 30].
Different measures of cellular functional/structural
changes have been used to indicate cell toxicity due to RCM
as outlined in the Table 2.
3. Radiocontrast Agents Cause Renal
Hypoxia-Role of Reactive Oxygen Species
Many studies have reported that administration of radiocon-
trast agents causes a decrease in renal medullary oxygena-
tion [31]. This may be due to mechanical factors such as
increased blood viscosity (in part related to red blood cell
aggregation) and urine viscosity as well as changes in the
levels of vasoactivemediators such as endothelins, natriuretic
peptides, nitric oxide, adenosine, and prostaglandins [31]. It
has also been proposed that the medullary hypoperfusion is
caused by constriction of the descending vasa recta (DVR)
due to cytotoxic damage of the endothelial cells of the DVR
caused by RCM [32]. Using isolated perfused human and
rat DVR [32], it was observed that the IOCM iodixanol at
physiologically relevant concentrations caused constriction
of DVR and caused structural damage of endothelial cells
from rat renal interlobular arteries. Thus, it is possible that
such RCM-induced effects lead to reduced medullary blood
flow in the kidney. A decrease in blood flow and hence in
oxygen supply may lead to perturbations in the mitochon-
drial electron transport chain leading to the production of
reactive oxygen species (ROS) that may have a detrimental
effect within the cell by oxidizing membrane lipids, inacti-
vating proteins, oxidizing DNA, and activating cell signalling
pathways leading to inflammation and cell death [33, 34].
In vitro studies have suggested that RCM may also lead
to ROS production. Sendeski et al., using isolated single
specimens of rat descending vasa recta (DVR), demonstrated
that iodixanol caused vasoconstriction of the DVR, and the
use of the superoxide dismutase (SOD) mimetic Tempol
reduced this iodixanol-induced vasoconstriction [35]. In
addition to demonstrating that iodixanol causes structural
damage to endothelial cells from isolated arteries, the same
group has demonstrated that iodixanol caused an increased
permeability of HUVEC (human umbilical vein endothelial
cell)monolayers and an increased phosphorylation ofmyosin
light chain, an indicator of endothelial cell retraction and
increased permeability [32]. Hence, it is feasible that RCM
may penetrate through the cell membrane and once in
the cytosol may also inflict similar damage to intracellular
organelles. Indeed, plasma membrane damage (measured as
loss of the membrane proteins caveolin and NaK-ATPase)
andmitochondrial damage (cytochrome c release) by ioversol
has been reported [9]. As mentioned earlier, disruption of
mitochondria may lead to the production of ROS and this
may be how RCM can induce the formation of ROS in
vitro without the need for hypoxia [34, 36]. Zager et al.
[9] questioned the role of oxidative stress in RCM renal
tubular and cell injury. They found that plasma membrane
damage to proximal tubule segments isolated from mice and
subjected to the LOCM, ioversol, was not due to oxidant
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Table 1: Iodinated contrast media commonly used in clinical practice.
Name Type Iodine content Osmolality Osmolality type
(mg/mL) (mOsm/kg)
Ionic
Diatrizoate (Hypaque 76) Monomer 370 2,016 HOCM
Metrizoate (Isopaque 370) Monomer 370 2,100 HOCM
Iothalamate (Conray 400) Monomer 400 2,300 HOCM
Ioxaglate (Hexabrix) Dimer 320 580 LOCM
Nonionic
Iopamidol (Isovue 370) Monomer 370 796 LOCM
Iohexol (Omnipaque 350) Monomer 350 884 LOCM
Iopromide (Ultravist 370) Monomer 370 774 LOCM
Ioversol (Optiray 350) Monomer 350 792 LOCM
Iomeprol (Iomeron 400) Monomer 400 720 LOCM
Iobitridol (Xenetix 350) Monomer 350 915 LOCM
Iodixanol (Visipaque 320) Dimer 320 290 IOCM
Iotrolan (Isovist 300) Dimer 300 320 IOCM
Ionic and nonionic contrast media may be monomeric or dimeric; 3 iodine atoms are present on each benzene ring of the contrast medium: if a contrast
molecule contains only 1 benzene ring, it is called a monomer, if it contains 2 benzene rings, it is called a dimer. In solution, ionic contrast media break up into
their anion and cation components, thereby increasing osmolality, while nonionic contrast media do not break up in solution. Nonionic dimers are the ideal
contrast media as they deliver the most iodine with the least effect on osmolality.
The osmolality of contrast media is compared with the osmolality of plasma. HOCM (high-osmolar contrast media) have the highest osmolality, that is, 5–8
times the osmolality of plasma. LOCM (low-osmolar contrast media) have an osmolality still higher than plasma, which is, 2-3 times the osmolality of plasma.
IOCM (iso-osmolar contrast media) have the same osmolality as plasma.
stress since no lipid peroxidation of the tubules was observed.
Furthermore, using HK-2 cells, Zager et al. [9] observed
that the antioxidant N-acetylcysteine (NAC) failed to protect
against RCM toxicity as assessed by lactate dehydrogenase
release and MTT reduction.
However, more recent work using a recombinant man-
ganese superoxide dismutase (SOD) administered in vivo to
rats undergoing diatrizoate treatment caused an improve-
ment in the glomerular filtration rate and a reduction in
renal histologic damage [37]. But the use of antioxidants
as therapeutic agents for the alleviation of CIN has yielded
conflicting data. The use of the antioxidant NAC had been
suggested as a means of reducing CIN in patients [38], but
successive trials have been contradictory [39], and recently
the Acetylcysteine for Contrast-induced nephropathy Trial
(ACT) has concluded that NAC does not reduce the risk
of CIN [40]. Other antioxidants have been reported to be
effective. In a clinical trial, administration of ascorbic acid
(vitamin C) protected against CIN, whilst in an animal
model rats fed with doses of alpha-tocopherol (vitamin
E) before iopromide injection showed decreased tubular
injury due to the RCM, increased SOD levels, and reduced
malondialdehyde levels [41]. Furthermore, rats fed with the
grape seed proanthocyanidin extract and treated with the
HOCM diatrizoate showed decreases in biochemical mark-
ers of oxidative stress, apoptosis, and renal tissue damage
caused by the RCM. Hizoh and Haller [20] observed a
protective effect by taurine on DNA fragmentation induced
by RCM in MDCK cells but not by NAC. Nonetheless, it
should be mentioned that intracellular peroxide levels in
cultured glomerularmesangial cells increased upon exposure
to diatrizoate and iohexol, and those levels were attenuated
by alpha-tocopherol in diatrizoate-treated but not in iohexol-
treated cells [42]. Nonetheless, it has been argued that the
oxidative stress observed with the use of RCM may be a
consequence of the toxicity of the RCM rather than the cause
[8].
4. RCM Effects on Endothelin Release
RCM have been reported to induce the release of the potent
vasoconstrictor peptide endothelin (ET) both in vivo and
in vitro, as well as upregulating ET mRNA transcription
[43–45] and also mediating the upregulation of the renal
medullary endothelin converting enzyme-1 expression and
synthesis [46]. It is believed that the ET-A receptor is involved
in vasoconstriction, whilst stimulation of the ET-B receptor
has the opposite effect. A study in humans receiving RCM
in which both ET receptors were blocked, resulted in a
higher incidence of CIN in patients receiving the blocker
than those receiving a placebo [47]. However, the use of a
specific ET-A antagonist gave a more positive outcome in an
in vivo rat study, but this was explained by inhibitory effects
of the antagonist on tubular transport mechanisms, thereby
decreasing the oxygen demand and reducing hypoxia [48].
5. Role of Adenosine in CIN
Adenosine is a product of ATP degradation and may arise
under the hypoxic conditions arising from RCM adminis-
tration. Whilst it may cause vasodilatation in most vessels,
adenosine causes vasoconstriction in the renal vasculature
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Table 2: Summary of some in vitro cell culture studies using different types of RCM.
Authors/year of publication Radiocontrast media used; cell type used Cell functional/structural changes observed
Laerum 1983 [11] HOCM and LOCM; human endothelialcells
Chromium-51 release as measure of cell toxicity;
HOCMmore toxic than LOCM
Andersen et al. 1994 [12] Ionic monomeric/dimeric, nonionicLOCM; MDCK and LLC-PK1 cells
RCM caused formation of large cytoplasmic vacuoles;
increase in brush border and lysosomal marker enzyme
activity
Dascalu and Peer 1994 [13] Ionic/nonionic RCM; endothelial andrenal cells Acidification of internal pH; decrease in cell viability
Andersen et al. 1995 [14] Nonionic LOCM and IOCM; MDCK andLLC-PK1 cells
RCM caused concentration-dependent formation of
large cytoplasmic vacuoles; cell death/decrease in cell
viability; increase in brush border and lysosomal
marker enzyme activity. These effects were more
pronounced with LOCM than with IOCM
Potier et al. 1997 [15] Ionic/nonionic LOCM and HOCM;mesangial cells
Dye uptake as measure of cell viability
HOCMmore toxic than LOCM
Haller et al. 1997 [16] HOCM and LOCM; MDCK andLLC-PK1 cells
HOCMmore toxic. LLC-PK1 cells more susceptible to
RCM cytotoxicity
Hizo´h et al. 1998 [17] MDCK; HOCM DNA fragmentation caused by RCM
Hardiek et al. 2001 [18] LLC-PK1 cells and human renal proximaltubule cells; HOCM, LOCM, and IOCM
Cell viability was affected by all RCM with HOCM
having a greater affect than IOCM which in turn had a
greater effect than LOCM
Fanning et al. 2002 [19] Human neutrophils; HOCM, LOCM, andIOCM
All types of RCM induced neutrophil apoptosis, with
HOCM having greater effect
Hizoh and Haller 2002 [20] MDCK cells; HOCM HOCM induced DNA fragmentation
Yano et al. 2003 [21] LLC-PK1 cells; HOCM and LOCM HOCM caused a greater decrease in cell viability
Ribeiro et al. 2004 [22] Renal artery smooth muscle cells; HOCMand LOCM HOCM caused a greater decrease in cell viability
Heinrich et al. 2005 [23] LLC-PK1 cells; HOCM, LOCM, andIOCM
All types of RCM cause a decrease in cell viability with
HOCM showing greatest effect
Andreucci et al. 2006, 2011, 2014
[24–26] HK-2 cells; HOCM, LOCM, and IOCM
All RCM caused a decrease in cell viability in the order
HOCM > LOCM > IOCM
Heinrich et al. 2007 [27] LLC-PK1 cells; LOCM and IOCM Cell viability measured; no difference in toxicitybetween the 2 types of RCM
Yang et al. 2013 [28] LOCM (ioversol); rat renal proximaltubular cell line (NRK-52E)
Decrease in cell viability and increase in intracellular
Ca2+ ion concentration
[49], thereby worsening the hypoxic conditions in the kidney
parenchyma. Hence, unselective (theophylline) and adeno-
sine A1-receptor selective antagonists have been used to
prevent CIN with some reported positive outcomes [50, 51].
In vitro mitochondrial damage by RCM may lead to disrup-
tion of the electron transport chain which, as in hypoxic
conditions, will lead to ATP degradation and adenosine
production. The adenosine produced may act as a substrate
for xanthine oxidase leading to production of the ROS,
hydrogen peroxide, which would be harmful [52]. However,
whilst it has been observed that RCM can increase adenosine
levels threefold in cultured HK-2 cells, inhibition of xanthine
oxidase with oxypurinol did not confer protection [9].
6. RCM May Impair Nitric Oxide (NO)
Production
In a study by Ribeiro et al. [22], using cultured smoothmuscle
cells obtained from rat renal artery, HOCM and LOCM but
not IOCM were found to lower NO levels. Thus, in this
case RCM may act to block a vasodilatory pathway. It has
been suggested that one mechanism by which NO levels are
lowered is by reactionwith superoxide ions that are generated
in the kidney by the RCM [53] which would lead to the
formation of the even more potent oxidant peroxynitrite
anion [54].
7. Cellular Signalling Pathways
Affected by RCM
Over the course of the last two decades, our knowledge
of signal transduction pathways by which cells respond to
changes in their environment has increased immensely.These
intracellular signalling pathways may determine cell fate,
for example, death, survival, proliferation, and release of
hormones, and may be triggered by mechanical, chemical,
light, and thermal stimuli.
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7.1. Pathways Involved in Cell Survival and Proliferation.
Saito et al. [55] reported a reduction in cyclic adenosine
monophosphate (cAMP) levels inmast cells.This was quickly
followed by reports of the LOCM ioversol inducing apoptosis
in LLC-PK1 cells [21]. Incubation of LLC-PK1 cells with
ioversol for 30 minutes followed by a further incubation
for 24 h in the absence of the RCM caused an increase in
the activities of caspases-3 and -9 (proteases involved in
apoptosis) and an increase in the mRNA for the proapoptotic
protein Bax, whilst the mRNA levels of the antiapoptotic
Bcl-2 decreased. It was also found that use of the cAMP
analogue dibutyl(DB)cAMP reversed the changes in a way
that was dependent on the signalingmolecules protein kinase
A (PKA) and phosphatidylinositol 3-kinase (PI 3-K). The
same group also found that the prostaglandin I2 analogue
beraprost sodium could also reverse the effects of ioversol
on caspases and Bax/Bcl-2 [56] by phosphorylation of the
cAMP-responsive element binding protein (CREB) via a
PKA-dependent mechanism. Further studies, again using
LLC-PK1 cells, suggested that the prosurvival kinase Akt may
also be involved in the effects of beraprost sodium [57].Work
from our laboratory has shown that incubation of HK-2 cells
with an HOCM (sodium diatrizoate), LOCM (iopromide
and iomeprol), and IOCM (iodixanol) causes the dephos-
phorylation of Akt at the Serine473 and Threonine308 sites
[24, 26]. This was accompanied by effects on downstream
targets of Akt such as p70S6 kinase (inactivated) which is
involved in protein synthesis and the FoxO (Forkhead-box)
family of transcription factors (dephosphorylated and hence
activated) [24]. Both diatrizoate and iopromide caused a
decrease in HK-2 cell viability which was partially alleviated
by transfection with plasmids encoding constitutively active
Akt [24]. Diatrizoate also caused a greater dephosphorylation
of mTOR (mammalian target of rapamycin) and ERK1/2
(extracellular signal regulated kinases 1/2) with respect to
iopromide, iomerol, or iodixanol [24, 26]. It should also
be noted that the dephosphorylation of Akt, p70S6 kinase,
and FoxO proteins was observed in primary cultures of
human proximal tubule cells [24]. It should be noted that
perturbations in the activity of kinases such as the ERK1/2 and
Aktmay affect the synthesis of vasodilatory and vasoconstric-
tory molecules. For example, endothelin-1 gene transcription
is negatively regulated by Akt and positively regulated by
FoxO1 [58], whilst COX-2 expression and prostaglandin
F2𝛼 synthesis may be dependent on ERK1/2 activity [59].
Akt has also been implicated in vasorelaxation [60]. West-
ern blot analysis of whole lysates prepared from kidneys
removed from rats treated with the LOCM iomeprol and
the IOCM iodixanol also showed lowered levels of phospho-
Akt (pAkt) and phospho-ERK1/2 (pERK1/2) compared with
lysates obtained from control nontreated rats [26]. An earlier
study using the LOCM ioversol also indicated that RCM
may cause a decrease in the basal levels of pAkt in mouse
kidneys [61]. These authors suggested that RCM enhance de
novo ceramide synthesis and cause the activation of protein
phosphatase 2A (PP2A) which in turn can dephosphorylate
Akt. However, PP2A may also act as an ERK- and JNK-
phosphatase [62], but our in vitro results show discrepancy
between the effects of RCM on the phosphorylation status of
Akt, ERK1/2, and the JNK (c-jun N-terminal kinase) family
of mitogen activated protein kinases (MAPKs). Nonetheless,
Itoh et al. also found that use of ceramide synthase inhibitors
attenuated renal tubular cell injury induced by ioversol in
LLC-PK1 cells and reduced the decreased pAkt levels in
vivo. Our observations of the decrease in pAkt and pERK1/2
by RCM was surprising since RCM have been associated
with ROS production and our experience with HK-2 cells
is that these kinases are phosphorylated upon stimulation
with hydrogen peroxide [63, 64]. A possible explanation
for the decrease in phosphorylation of Akt may be due to
disruption of cell membrane rafts that organize membrane-
associated molecules such as receptors and kinases and reg-
ulate cellular signal transduction [65]. It has been proposed
that these membrane rafts allow for the close proximity and
interaction between Akt and kinases that phosphorylate it,
for example, PDK-1 (phosphoinositide-dependent kinase-1),
and any perturbation of the raft structure may interfere with
the phosphorylation of Akt. Given the already mentioned
physical impairment of the cell membrane by RCM [9, 32],
it is possible that RCM could be affecting signalling pathways
in this way.
7.2. Pathways Involved in Cell Death and Inflammation. Our
group also demonstrated the phosphorylation of the p38 and
JNK MAPKs, and of the transcription factor NF-𝜅B (Ser
276) by sodium diatrizoate and iomeprol in HK-2 cells [25].
Sodium diatrizoate had a greater effect than iomeprol (at the
same concentration of iodine) on phosphorylation of these
molecules, which have been implicated in inflammation and
upregulation of the proinflammatory cytokine IL-8 [66, 67].
Incubation of HK-2 cells with HOCM, LOCM, and IOCM
at concentrations of 75 and 100mgI/mL for up to 3 h did
not result in caspase-3 cleavage [26]. However, in HK-2 cells
that had been previously exposed to diatrizoate for 2-3 h
and then incubated for a further 22 h (after removal of the
RCM), caspase-3 cleavage was observed [25, 26]. It should
be noted that the presence of phosphorylated JNKs was
detected in renal tubular epithelial cells collected from urine
samples of patients, 24 h and 48 h after RCM administration
[68]. A possible role for the transcription factor NF-𝜅B was
also suggested by Xu et al. [69] who noted that the DNA-
binding activity of NF-𝜅B in rat increased after diatrizoate
administration.
In contrast, Romano et al. have demonstrated that both
LOCM and IOCM caused a marked increase in caspases-3
and -9 activities and poly(ADP-ribose) polymerase fragmen-
tation in HEK293 cells; no effect was observed by them on
caspase-8 and -10, thus indicating that the RCM activated
apoptosis mainly through the intrinsic pathway [10]. Both
RCM induced an increase in protein expression levels of
proapoptotic members of the Bcl2 family, Bim and Bad.They
also demonstrated that pretreatment with NAC and ascorbic
acid but notwith sodiumbicarbonate could prevent apoptosis
in a dose-dependent fashion.
Using HEK293T cells, Lee et al. [70] analyzed the effects
of four different contrast media: ionic high-osmolar diatri-
zoate, ionic low-osmolar iothalamate, nonionic low-osmolar
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iohexol, and nonionic iso-osmolar iodixanol. They showed
that diatrizoate, iodixanol, and iothalamate, but interestingly
not iohexol, induced the expression of ATF-2 (activating
transcription factor-2) mRNA and phosphorylation of ATF-
2 in HEK293T cells in a time-dependent manner. More
apoptotic cells were detected in diatrizoate-treated kidney
cells than in the saline injection group. Cell death was
significantly increased by knockdown ATF-2 expression in
the presence of diatrizoate, indicating a protective role of
ATF-2 in contrast media-induced apoptosis. Despite the
study’s limitations, such as the absence of any control
conditions (e.g., the use of hyperosmolar solutions since
diatrizoate is a high-osmolar RCM) in assessing the role
of hypertonicity in CIN pathogenesis and their choice of
cells that did not include an adult human proximal tubule
cell line (such as HK-2 cells), the work provided new
evidence that iodinated contrast media, with the exception
of iohexol (a nonionic LOCM), could activate the JNK/ATF-
2 signaling pathways. So, this provided a new insight into
the mechanism and a potential way of prevention of CIN,
showing a differential activation of ATF-2 by different RCM
[70].
Gong et al. studied the apoptotic signaling mechanism in
CIN and testedwhether the new antioxidantN-acetylcysteine
amide (NACA) could prevent it, using the RCM iohexol.
In this study [71], LLC-PK1 cells were exposed to iohexol
in order to observe their cell death with apoptotic features
in a dose- and time-dependent manner; they showed that
the initiation of iohexol-induced apoptosis was mediated by
upregulation of Bax and downregulation of Bcl-2 and Mcl-1
(another anti-apoptotic protein), which was preceded by p38
MAPK activation and iNOS (inducible nitric oxide synthase)
induction.The use of inhibitors of p38MAPK and iNOS par-
tially abolished iohexol-induced apoptosis. They also found
that pretreatment with NACA partially protected cells from
iohexol-induced death by reverting the expression of Bcl-2,
Mc1-1, and Bax expression through inhibition of p38 MAPK
and iNOS pathway. NACA, partially protecting LLC-PK1
cells from iohexol-induced apoptosis by suppression of p38
MAPK activation and iNOS protein expression, was more
effective than NAC, a widely used antioxidant compound.
The authors claimed that a possible explanation is that NACA
has better membrane permeation and could therefore be
expected to be even more effective than NAC in vivo [71].
However, our study with p38 MAPK inhibition only yielded
a small increase in cell viability after exposure of HK-2 cells
to diatrizoate [26].
Recently Gong et al. implicated the role of p38 MAPK
as well as FoxO1 pathways in RCM toxicity [72]. Using an
experimental model of CIN in rats, they showed that tetram-
ethylpyrazine (TMP) could significantly attenuate the result-
ing renal dysfunction and renal tubular cellular apoptosis.
These functional changes were accompanied by the decreased
levels of phospho-p38 MAPK protein and attenuation of
the increased FoxO1 mRNA and nuclear protein expression
[72]. Figure 1 shows a summary of the signaling molecules
that play roles in cell death, survival, inflammation and in
vasoconstriction/vasodilation, as discussed above.
7.3. Cell Survival Pathways Induced by RCM. The cellular
stress evoked by RCM has also been shown to prompt an
unfolded protein response [UPR] (which is believed to be
a prosurvival response) in a rat renal proximal tubular cell
line NRK-52E [73]. Wu et al. found that treatment of the
cells with diatrizoate caused the expression of the chaperones
GRP (Glucose regulated protein) 78 and GRP94 which act
to protect the cell under conditions of stress. Furthermore,
GRP78 dissociates from the endoplasmic reticulum trans-
membrane receptor PERK [PKR (double-stranded RNA-
activated protein kinase) like ER kinase], and in so doing
allowing PERK to be activated.Wu et al. suggested that active
PERK phosphorylates and activates the eukaryotic initiation
factor (eIF)2𝛼, which in turn reduces RCM-induced cell
apoptosis [73].
Moon et al. [74] suggested that angiopoietin-1 (Ang1)may
protect vascular endothelial cells from iopromide-induced
apoptosis through PI 3-K and mTOR/S6 kinase, postulating
that the pretreatment with Ang1 could help in maintaining
normal vascular endothelial cell integrity before and during
systemic RCM administration. In that work Ang1 reduced
iopromide-induced apoptosis in a dose-dependent manner.
Two PI 3-K inhibitors, wortmannin and LY294002, decreased
the Ang1-induced anti-apoptotic effect. Since Ang1 mediates
the activation of mTOR/ribosomal protein p70 S6 kinase
through PI 3-K, wortmannin, and rapamycin, an inhibitor of
mTOR, suppressedAng1-induced p70S6 kinase phosphoryla-
tion and partially inhibited the Ang1-induced anti-apoptotic
effect [74].
Yokomaku et al. have suggested that asialoerythropoi-
etin may have potential as a new therapeutic approach to
prevent CIN, given its ability to preserve renal function
and directly protect renal tissue, as demonstrated in rats,
in which nephropathy was induced by injection with the
RCM ioversol, in addition to inhibition of prostaglandin
and nitric oxide synthesis [75]. The administration of a
single dose of asialoerythropoietin before the induction of
nephropathy could significantly attenuate the resulting renal
dysfunction and the histologic renal tubular injury. RCM-
induced apoptosis of renal tubular cells was inhibited by
asialoerythropoietin both in vivo and in vitro, and this effect
was blocked by a Janus kinase 2 (JAK2) inhibitor in vitro. Fur-
thermore, phospho-JAK2/signal transducer and activator of
transcription 5 (STAT5) andheat-shock protein 70 expression
increased after injection of asialoerythropoietin, suggesting
that the effects of asialoerythropoietin might be mediated by
the activation of the JAK2/STAT5 pathway.
Another cellular mechanism that may be protective
against RCM injury was reported by Goodman et al. [76].
They demonstrated that heme oxygenase-1 induction by
cobalt protoporphyrin could prevent the increase in plasma
creatinine and in superoxide ion formation in both the cortex
and medulla in uninephrectomized, salt depleted male Sabra
rats treated with the RCM sodium iothalamate compared
with untreated rats.This protective effect of heme oxygenase-
1 was associated with increased anti-apoptotic proteins Bcl-2
and Bcl-xl and with a decrease of proapoptotic caspase-3 and
caspase-9 together with increased expression of inactive Bax.
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Figure 1: Scheme showing the effects of RCM on signaling molecules. The scheme relates to effects on signaling molecules that may
underlie the toxic effects of RCM. RCM cause inactivation of the kinase Akt (as shown by the minus symbol) leading to activation of FoxO
transcription factors which may lead to cell death; upregulation of ET-1 transcription and hence vasoconstriction; deactivation of the p70S6
kinase and hence downregulation of protein synthesis. ERK1/2 are also inactivated which may lead to a decrease in activity of COX-2 and
prostaglandin production and hence inhibition of vasodilation. RCM also downregulate cAMP and hence the cAMP dependent kinase PKA.
The antiapoptotic protein Bcl-2 is downregulated, whilst the proapoptotic proteins Bax, Bim, Bad, and caspases-3 and -9 are upregulated
(as shown by the plus symbol) by RCM. The JNK and p38 MAP kinases are activated as also is the transcription factor NF-𝜅B, all three of
which may play a role in cell death and inflammation. Hypoxia and mitochondrial damage caused by RCM may lead to the formation of
ROS (reactive oxygen species) that can cause cell death and inflammation; and to the formation of adenosine that can cause vasoconstriction,
whilst its metabolism by xanthine oxidase can lead to further formation of ROS.
8. Conclusions
It is clear that RCM induce a drastic effect both in vitro
and in vivo. Whilst in vivo they cause changes in the tissue
environment causing hypoxic conditions and changes in
levels of vasoconstrictory and vasodilatory factors that may
exacerbate the hypoxic milieu, in vitro cell culture studies
have demonstrated that RCM cause changes in a variety of
cell signaling molecules that play important roles in cellular
homeostasis. These include the deactivation of molecules
such as Akt and ERK1/2 that enable cells to survive stress and
to proliferate as well as to regulate the synthesis of vasoactive
molecules. At the same time other molecular species are
increased or activated that may be detrimental, such as ROS
and signalling molecules such as the p38 and JNK kinases
and transcription factors such asNF-𝜅B thatmaymediate cell
death and inflammation [77]. Delineation of the molecular
mechanisms of RCM may help future strategies to reduce
their detrimental effects.
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